20-NOV-2024 6:10

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY ADMIN CCADMIN ACCR.
GOAL		 R
E
G		 O
P
E
N		 ARM TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol PEOLC   491 1 Y 0 Screening 329 4 0 0 0 0
              329 4 0 0 0 0
 
        2 Y 1 Carvedilol 74 2 0 0 0 0
            2 No prophylaxis 81 4 0 0 0 0
            3 Observation 155 0 0 0 0 0
              310 6 0 0 0 0
 
S1703-Met Breast, STM-monitoring v Usual Care CCD SXQOL 739 1 Y 0 Screening 548 86 50 30 10 2
              548 86 50 30 10 2
 
        2 Y 1 Control (Usual Care) 184 32 16 7 5 0
            2 Intervention (STMDDM) 185 33 15 9 5 1
              369 65 31 16 10 1
 
S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum GU SXQOL 1273 1 Y 0 Induction SST 864 123 61 23 7 1
              864 123 61 23 7 1
 
        2 Y 1 Standard Systemic Therapy Only 310 45 27 14 4 0
            2 SST + Surgery/RT 312 51 30 13 2 0
              622 96 57 27 6 0
 
S1803-MM, Maintenance, Len vs Len/Dara MMYEL SXQOL 1420 1 Y 0 Screening 1383 242 140 75 30 4
              1383 242 140 75 30 4
 
        2 Y 1 Lenalidomide 636 108 64 34 13 1
            2 Lenalidomide + Daratumumab 627 110 63 32 13 1
              1263 218 127 66 26 2
 
        3 Y 3 Continue Lenalidomide 32 9 5 2 1 0
            4 Stop Lenalidomide 34 10 6 4 0 0
            5 Continue Lenalidomide + Dara 76 25 12 6 2 1
            6 Stop Lenalidomide + Dara 77 26 13 8 2 0
              219 70 36 20 5 1
 
S1827-SCLC, MRI Surveillance +/- PCI LUNG SXQOL 668 1 Y 1 PCI + MRI brain surveillance 124 30 14 7 2 0
            2 MRI brain surveillance 123 33 12 7 5 1
              247 63 26 14 7 1
 
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship CCD   326 1 Y 1 Financial Navigation 159 89 39 23 7 3
            2 Control 161 88 43 20 8 3
              320 177 82 43 15 6
 
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP LYMPH SXQOL 422 1 Y 1 CC-486 + R-miniCHOP 62 25 11 5 3 1
            2 R-miniCHOP 60 24 10 3 2 1
              122 49 21 8 5 2
 
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O LEUK SXQOL 247 1 Y 1 Delayed V-O 41 12 5 2 0 0
            2 Early V-O 79 25 12 6 2 1
              120 37 17 8 2 1
 
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed SXQOL   540 1 Y 1 Active Symptom Monitoring + Patient Education 245 179 88 48 18 0
            2 Patient Education 246 181 90 50 21 2
              491 360 178 98 39 2
 
S2013-I-CHECKIT: ICI toxicity risk prediction study SXQOL   3609 1 Y 1 Observation Arm 2084 506 0 0 0 0
              2084 506 0 0 0 0
 
S2108CD-Genomic Tumor Board vs Usual Practice CCD   1282 1 Y 1 Usual Practice 609 289 154 89 29 4
            2 EGTB Intervention 666 288 116 57 18 2
              1275 577 270 146 47 6
 
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes SXQOL   777 1 Y 1 Cryocompression 84 69 37 18 6 3
            2 Continuous Compression 84 69 35 20 4 2
            3 Low Cyclic Compression 84 68 36 17 7 0
              252 206 108 55 17 5
 
S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva BREAST SXQOL 960 1 Y 1 Tissue for MammaPrint testing 253 253 183 109 33 8
              253 253 183 109 33 8
 
        2 Y 2 SOC Chemotherapy 42 42 34 22 7 1
            3 SOC Chemotherapy + Durvalumab 41 41 33 21 8 3
              83 83 67 43 15 4
 
S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa LYMPH SXQOL 227 1 Y 1 Tazemetostat (Arm 1) Dose Level 1 7 6 2 0 0 0
            4 Zanubrutinib (Arm 3) Dose Level 1 10 7 0 0 0 0
            5 Zanubrutinib (Arm 3) Dose Level 2 10 10 10 4 3 0
              27 23 12 4 3 0
 
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D MMYEL SXQOL 510 1 Y 1 VRD-R 16 15 8 5 3 1
            2 DRD-R 16 16 8 4 1 0
            3 DRD-DR 17 15 9 6 2 0
              49 46 25 15 6 1
 
S2212-Breast, TNBC, Neoadj Chemo + Pembro BREAST SXQOL 2400 1 Y 1 Carbo + Paclitaxel + Pembro -> AC + Pembro 188 182 114 63 24 5
            2 Carbo + Docetaxel + Pembro 190 182 119 69 24 7
              378 364 233 132 48 12
 
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT MMYEL SXQOL 338 1 Y 0 Induction 5 5 5 3 1 0
              5 5 5 3 1 0
 
        2 Y 1 Dara-VCD 1 1 1 1 1 0
              1 1 1 1 1 0
 
        3 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo GI SXQOL 224 1 Y 1 Nivolumab + Paclitaxel + Ramucirumab 3 3 3 3 2 0
            2 Paclitaxel + Ramucirumab 4 4 4 2 0 0
              7 7 7 5 2 0
 
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib BREAST SXQOL   1 E   47 10 3 3 0 0
              47 10 3 3 0 0
 
A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab BREAST SXQOL   1 E   12 9 5 2 1 0
              12 9 5 2 1 0
 
A021806-Pancreas, Perioperative vs Adjuvant Chemo GI SXQOL   0 E   37 6 1 1 0 0
              37 6 1 1 0 0
 
        1 E   31 6 1 1 0 0
              31 6 1 1 0 0
 
A022001-PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM GI SXQOL   1 E   2 1 0 0 0 0
              2 1 0 0 0 0
 
A022004-Colon, Stg II-III, Encor+Cetux vs SOC GI SXQOL   0 E   14 14 10 4 0 0
              14 14 10 4 0 0
 
        1 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
A032103-Urothelial, All Stg, MRD-Based Adj Tx GU SXQOL   0 E   4 4 3 2 1 0
              4 4 3 2 1 0
 
        1 E   2 2 1 0 0 0
              2 2 1 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub LYMPH SXQOL   1 E   12 12 7 4 0 0
              12 12 7 4 0 0
 
        2 E   3 3 2 2 0 0
              3 3 2 2 0 0
 
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO LUNG SXQOL   1 E   87 20 11 5 0 0
              87 20 11 5 0 0
 
A211901-Cancer survivors who smoke, txt cessation SXQOL     1 E   13 10 6 1 0 0
              13 10 6 1 0 0
 
ACCL16N1-Guideline Consistent Treatment AYA ALL CCD     1 T   54 0 0 0 0 0
              54 0 0 0 0 0
 
AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy LYMPH SXQOL   1 E   30 21 13 7 2 0
              30 21 13 7 2 0
 
        2 E   23 21 10 7 3 0
              23 21 10 7 3 0
 
CCTGHN11-HN, All Stg, Guided Elec Contra Neck Tx OTHER SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
        2 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
EA5221-Lung, Advanced NSCLC, ChemoImmuno/Immuno LUNG SXQOL   1 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
        2 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) MMYEL SXQOL   0 E   50 11 4 4 0 0
              50 11 4 4 0 0
 
        1 E   37 9 2 2 0 0
              37 9 2 2 0 0
 
        2 E   27 14 8 4 0 0
              27 14 8 4 0 0
 
EAQ211-Lymph, Survivors, Health Disp. AYA SURV     1 E   1 1 1 1 1 0
              1 1 1 1 1 0
 
EAQ222CD-CostCOM, Cancer Patients, OOP Cost Com CCD     0 E   5 5 5 5 2 0
              5 5 5 5 2 0
 
        1 E   5 5 5 5 4 1
              5 5 5 5 4 1
 
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT BREAST SXQOL   1 E   42 20 13 7 3 0
              42 20 13 7 3 0
 
        2 E   41 19 13 7 3 0
              41 19 13 7 3 0
 
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction SXQOL OTHER   1 E   13 8 5 3 1 0
              13 8 5 3 1 0
 
NRGCC011-Breast, Survivors, Cog Training SXQOL     0 E   33 33 32 22 6 1
              33 33 32 22 6 1
 
        1 E   21 21 20 17 2 1
              21 21 20 17 2 1
 
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide GU SXQOL   1 E   14 4 1 0 0 0
              14 4 1 0 0 0
 
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx GU SXQOL   1 E   11 8 2 0 0 0
              11 8 2 0 0 0
 
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo LUNG SXQOL   1 E   2 2 1 1 0 0
              2 2 1 1 0 0
 
A021804-Adren, Advanced Stg, Temo w/wo Ola GU     1 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
A031801-GU, mRCC, Cabozantinib ± Radium-223 GU SXQOL   1 E   15 4 1 0 0 0
              15 4 1 0 0 0
 
A082002-Lung, Adv, Systemic Tx +/- SBRT LUNG SXQOL   1 E   4 1 0 0 0 0
              4 1 0 0 0 0
 
A191901-Brst, Text/Motivational Intervention ET Adher CCD     1 E   40 1 1 0 0 0
              40 1 1 0 0 0
 
A211801-Breast, Preventive, Denosumab PREV     0 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
        1 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
A212102-Blind Ref Set for Multicancer Early Detection PREV     1 E   163 102 63 32 13 4
              163 102 63 32 13 4
 
A222004-Mult, Olanza vs Megestrol for Anorexia SXQOL     1 E   7 5 4 1 0 0
              7 5 4 1 0 0
 
A231602C-Blood Cancer, Assess Financial Difficulty CCD     1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
A231901CD-Breast, Shared Decision Engagement System CCD     1 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
ACCL1931-Leuk, All Stg, Levocarnitine Prophylaxis SXQOL     1 E   2 2 0 0 0 0
              2 2 0 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL   1 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo OTHER SXQOL   1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
CCTGCO32-Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad GI SXQOL   1 E   3 3 3 2 0 0
              3 3 3 2 0 0
 
CCTGNE1-Midgut NET, Unresect, 177 Lut vs Ever GI SXQOL   1 E   3 3 3 2 0 0
              3 3 3 2 0 0
 
CE7-Brain, 5+ Metastases, Radiosurg/Radiotherapy OTHER SXQOL   1 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
        2 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
EA2185-Panc, Impact of Panc Cyst Surveillance PREV SXQOL   1 E   19 2 0 0 0 0
              19 2 0 0 0 0
 
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL   1 E   13 1 1 0 0 0
              13 1 1 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
EA8184-Pros, Dbl Blind GTC vs Placebo PREV SXQOL   0 E   23 15 9 7 2 0
              23 15 9 7 2 0
 
        1 E   9 5 4 2 2 0
              9 5 4 2 2 0
 
EA8191-Pros, Local vs Systemic Thrpy GU SXQOL   0 E   53 30 16 8 2 0
              53 30 16 8 2 0
 
        1 E   53 30 17 8 2 0
              53 30 17 8 2 0
 
EA8212-Blad, NMIBC, BRIDGE GU SXQOL   1 E   172 119 62 32 12 3
              172 119 62 32 12 3
 
EAA173-MYEL, SMM, Rd +/- Daratumumab MMYEL SXQOL   0 E   74 19 7 3 1 0
              74 19 7 3 1 0
 
        1 E   35 10 6 3 1 0
              35 10 6 3 1 0
 
EAQ202-Improving AYA PROs in EA Trials SXQOL     1 E   43 0 0 0 0 0
              43 0 0 0 0 0
 
NRGBN003-Mening, Grd II, Observation vs Irradiation OTHER SXQOL   1 E   5 0 0 0 0 0
              5 0 0 0 0 0
 
        2 E   3 0 0 0 0 0
              3 0 0 0 0 0
 
NRGBN011-Brain, Lomustine + Temo vs Temo OTHER SXQOL   1 E   29 17 12 7 4 0
              29 17 12 7 4 0
 
        2 E   8 4 4 3 2 1
              8 4 4 3 2 1
 
NRGBN012-Brain, Pre- vs Post-Op Stereotactic Radiosurg OTHER SXQOL   1 E   4 3 3 0 0 0
              4 3 3 0 0 0
 
NRGBR007-Breast, Stg I, De-Escalation of Breast RT BREAST SXQOL   1 E   12 6 4 1 0 0
              12 6 4 1 0 0
 
        2 E   12 6 4 1 0 0
              12 6 4 1 0 0
 
NRGBR009-Breast, EarlyStg, Adjuvant Chemo BREAST SXQOL   1 E   7 7 4 1 1 0
              7 7 4 1 1 0
 
        2 E   7 7 4 1 1 1
              7 7 4 1 1 1
 
NRGCC005-Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs PREV     1 E   26 26 21 10 4 1
              26 26 21 10 4 1
 
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO PREV SXQOL   1 E   11 5 2 1 0 0
              11 5 2 1 0 0
 
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy GI SXQOL   1 Y   15 0 0 0 0 0
              15 0 0 0 0 0
 
NRGGI006-Esophagus, Stg I-IVA, PBT vs IMRT GI SXQOL   1 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
        2 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
NRGGU009-Pros, PREDICT-RT GU SXQOL   1 E   85 49 28 12 4 0
              85 49 28 12 4 0
 
        2 E   80 51 30 11 4 3
              80 51 30 11 4 3
 
NRGGU010-Pros, Parallel De-Intens & Intens Trials GU SXQOL   1 E   62 36 25 17 6 1
              62 36 25 17 6 1
 
        2 E   55 32 22 16 6 2
              55 32 22 16 6 2
 
NRGGU013-Prostate, High-Risk, Five Fraction Radiation GU SXQOL   1 E   5 5 5 2 1 1
              5 5 5 2 1 1
 
NRGGY026-Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE OTHER SXQOL   1 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
NRGHN006-HN, Erly Stg, Biopsy vs Dissection OTHER SXQOL   1 E   3 2 2 0 0 0
              3 2 2 0 0 0
 
        2 E   3 1 1 0 0 0
              3 1 1 0 0 0
 
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN OTHER SXQOL   1 E   17 9 3 1 0 0
              17 9 3 1 0 0
 
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux OTHER SXQOL   1 E   6 0 0 0 0 0
              6 0 0 0 0 0
 
        2 E   5 0 0 0 0 0
              5 0 0 0 0 0
 

20-NOV-2024 6:10

Cancer Coltrol Open Studies with No Registrations

Study Admin CCAdmin Registration/Phase Open Date
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT MMYEL SXQOL 3 Maintenance 01-Dec-23
A022004 Colon, Stg II-III, Encor+Cetux vs SOC GI SXQOL 1 Registration 30-May-23
A032103 Urothelial, All Stg, MRD-Based Adj Tx GU SXQOL 2 Re-Registration 09-Jan-24
ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis SXQOL   2 Callback 14-Aug-23
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL 2 Late Randomization Callback 08-May-17
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL 2 Randomization2 08-Sep-17